Novavax Inc (NVAX): Total Assets
$1.18B
As of 2025-12-31
$955.58M
As of 2026-06-30
-19.5%
3-year compound annual growth
-5.8%
5-year compound annual growth
+11.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.18B | -24.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.56B | -13.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $1.80B | -20.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $2.26B | -12.3% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $2.58B | +62.8% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $1.58B | +815.0% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $172.96M | -16.8% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $207.98M | -31.2% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $302.49M | -23.3% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $394.30M | +2.1% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $386.04M | +39.9% | 2017-02-27, Balance as of period end |
| 2014-12-31 | $276.00M | +17.4% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $235.12M | +129.7% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $102.34M | +53.7% | 2014-03-12, Balance as of period end |
| 2011-12-31 | $66.58M | -11.0% | 2013-03-12, Balance as of period end |
| 2010-12-31 | $74.84M | n/a | 2012-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Novavax Inc (NVAX) | 2025-12-31 | $1.18B | -24.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $514.16M | +4.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $624.24M | +27.7% |
Compare NVAX, TECH, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗